Page last updated: 2024-12-06
hrp 112
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
CycloProvera: contains medroxyprogesterone acetate & estradiol cypionate; contains 25 mg medroxyprogesterone acetate and 5 mg estradiol-cypionate [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 62995 |
| MeSH ID | M0106385 |
Synonyms (10)
| Synonym |
|---|
| lunelle |
| 71615-27-5 |
| hrp 112 |
| cycloprovera |
| hrp112 |
| pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6-alpha)-, mixt. with (17-beta)-3-hydroxyestra-1,3,5(10)-trien-17-yl cyclopentanepropanoate |
| cyclofem |
| 3-hydroxyestra-1(10),2,4-trien-17-yl 3-cyclopentylpropanoate--6-methyl-3,20-dioxopregn-4-en-17-yl acetate (1/1) |
| DTXSID40992177 |
| [(6s,8r,9s,10r,13s,14s,17r)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate;[(8r,9s,13s,14s,17s)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] 3-cyclo |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " The adverse events reported in both treatment groups are consistent with those expected with the use of combined hormonal contraceptives." | ( Comparative safety, efficacy, and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Lu Cromie, MA; Garceau, RJ; Kaunitz, AM, 1999) | 0.3 |
Pharmacokinetics
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Serum progesterone levels and, consequently, ovulation were suppressed beyond the entire dosing interval, indicated by the absence of any luteal-like progesterone peaks (serum progesterone concentrations did not exceed 1 ng/mL)." | ( Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): assessment of return of ovulation after three monthly injections in surgically sterile women. Rahimy, MH; Ryan, KK, 1999) | 0.3 |
| " Serum progesterone levels and, consequently, ovulation were suppressed beyond the entire dosing interval, indicated by the absence of any luteal-like progesterone peaks." | ( Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): assessment of return of ovulation after three monthly injections in surgically sterile women. Rahimy, MH; Ryan, KK, 1999) | 0.3 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (63)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (9.52) | 18.7374 |
| 1990's | 36 (57.14) | 18.2507 |
| 2000's | 20 (31.75) | 29.6817 |
| 2010's | 1 (1.59) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 10.41
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (10.41) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 32 (47.76%) | 5.53% |
| Reviews | 17 (25.37%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (26.87%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||